Clinical Trials Logo
  1. Home
  2. Type I Hypersensitivity
  3. NCT00387478

Investigation of Efficacy and Safety of Tree MATAMPL,Tree MATA, and Placebo in Patients With Birch-Induced Seasonal Allergic Rhinitis

Type I Hypersensitivity Clinical Trial

Official title:
A Double Blind Study to Investigate the Clinical Efficacy and Safety of TreeMATAMPL (Allergy Therapeutics, (UK) Ltd.), TreeMATA (Allergy Therapeutics, (UK) Ltd.) and Placebo in Patients With Seasonal Allergic Rhinitis Due to Birch Pollen Allergy, in an Environmental Exposure Chamber (EEC) Model When Exposed to Birch Pollen and Oak Pollen

Clinical Trial Summary

Tree MATAMPL has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to Tree (birch, alder, hazel) pollen (hay fever). This novel formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections administered before the start of the pollen season. In this Study the Efficacy will be assessed by exposing allergic subjects to birch pollen in an environmental exposure chamber EEC. Patient symptomatic response to birch pollen and patient quality of life in the EEC will be determined.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00387478
Study type Interventional
Source Allergy Therapeutics
Contact
Status Terminated
Phase Phase 2
Start date October 2006
Completion date July 2007
View Details
See also
  Status Clinical Trial Phase
Completed NCT00133159 - Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen Phase 2
Completed NCT00133146 - Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine Phase 2
Completed NCT00414141 - Efficacy and Safety/Tolerability of Grass MATA MPL Phase 3
Completed NCT00258635 - Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test Phase 2
Completed NCT00325338 - Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis Phase 2
Withdrawn NCT00109759 - Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A) Phase 1
Completed NCT00110786 - Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy Phase 2
Completed NCT00423787 - Efficacy and Safety/Tolerability of Ragweed MATA MPL Phase 3
Completed NCT00104377 - Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen Phase 2
Completed NCT00104390 - Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing Phase 1
Completed NCT00116285 - Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing Phase 1
Completed NCT00118612 - Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen Phase 2
Completed NCT00113750 - Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen Phase 2
Completed NCT00118625 - Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine Phase 2
Completed NCT00241410 - Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen Phase 1
Completed NCT00107705 - Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing Phase 1